Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
AstraZeneca PLC SECOND Quarter AND HALF YEAR Results 2014 London, 31 July 2014 Click on, or paste the following link into your web browser, to view the associated PDF...
-
AstraZeneca Second Quarter & Half Year Results 2014 Tomorrow, Thursday, 31 July 2014, AstraZeneca will release second quarter and half year results for 2014 at 07:00 bst. An analyst presentation of...
-
ASTRAZENECA AGREES STRATEGIC TRANSACTION WITH ALMIRALL IN RESPIRATORY DISEASE Business combination will provide boost to revenue as well as creating long-term value, strengthening AstraZeneca's...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 30 June 2014, Pascal Soriot, a Director of the Company, notified us that, on 30 June 2014, he purchased...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 26 June 2014, Marc Dunoyer, a Director of the Company, notified us that, on 25 June 2014, he purchased...
-
AstraZeneca today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 16 June 2014, we were notified that, on 11 June 2014, Dr Briggs Morrison, a person discharging managerial...
-
+-------------+-++++--------------+ | | | +-------------+-++++--------------+ | | | +-------------+-++++--------------+ | ...
-
Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 16 June 2014, the interest of Mr Marc Dunoyer, a person discharging managerial responsibilities, in the...
-
US FDA ADVISORY COMMITTEE RECOMMENDS NO CARDIOVASCULAR OUTCOMES TRIAL FOR PERIPHERALLY-ACTING MU-OPIOID RECEPTOR ANTAGONIST (PAMORA) CLASS INCLUDING MOVANTIK AstraZeneca announced today that the...